LungLife AI, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LLAI.L research report →
Companywww.lunglifeai.com
LungLife AI, Inc. , a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance.
- CEO
- Paul Pagano
- IPO
- 2021
- Employees
- 8
- HQ
- Thousand Oaks, CA, US
Price Chart
Growth & Income
- Revenue
- $46.00K · 91.67%
- Net Income
- $-5,413,000 · 28.83%
- EPS
- $-0.21 · 30.00%
- Op Income
- $-5,632,000
- FCF YoY
- 14.05%
Performance & Tape
- 52W High
- $21.70
- 52W Low
- $0.80
- 50D MA
- $2.26
- 200D MA
- $6.81
- Beta
- 0.37
- Avg Volume
- 447.72K
Get TickerSpark's AI analysis on LLAI.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LLAI.L Coverage
We haven't published any research on LLAI.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LLAI.L Report →